JP2010535026A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535026A5
JP2010535026A5 JP2010518815A JP2010518815A JP2010535026A5 JP 2010535026 A5 JP2010535026 A5 JP 2010535026A5 JP 2010518815 A JP2010518815 A JP 2010518815A JP 2010518815 A JP2010518815 A JP 2010518815A JP 2010535026 A5 JP2010535026 A5 JP 2010535026A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
influenza
peptide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010518815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535026A (ja
JP5654345B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2008/001062 external-priority patent/WO2009016639A2/en
Publication of JP2010535026A publication Critical patent/JP2010535026A/ja
Publication of JP2010535026A5 publication Critical patent/JP2010535026A5/ja
Application granted granted Critical
Publication of JP5654345B2 publication Critical patent/JP5654345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010518815A 2007-08-02 2008-08-03 多量体マルチエピトープインフルエンザワクチン Expired - Fee Related JP5654345B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95349807P 2007-08-02 2007-08-02
US60/953,498 2007-08-02
PCT/IL2008/001062 WO2009016639A2 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines

Publications (3)

Publication Number Publication Date
JP2010535026A JP2010535026A (ja) 2010-11-18
JP2010535026A5 true JP2010535026A5 (enExample) 2011-09-15
JP5654345B2 JP5654345B2 (ja) 2015-01-14

Family

ID=40305020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010518815A Expired - Fee Related JP5654345B2 (ja) 2007-08-02 2008-08-03 多量体マルチエピトープインフルエンザワクチン

Country Status (17)

Country Link
US (2) US8747861B2 (enExample)
EP (1) EP2173376B1 (enExample)
JP (1) JP5654345B2 (enExample)
KR (1) KR101580660B1 (enExample)
CN (1) CN101795709B (enExample)
AU (1) AU2008281384C1 (enExample)
BR (1) BRPI0815008B8 (enExample)
CA (1) CA2695399C (enExample)
DK (1) DK2173376T3 (enExample)
EA (1) EA017887B1 (enExample)
ES (1) ES2539818T3 (enExample)
HR (1) HRP20150479T1 (enExample)
HU (1) HUE025149T2 (enExample)
MX (1) MX2010001284A (enExample)
PL (1) PL2173376T3 (enExample)
PT (1) PT2173376E (enExample)
WO (1) WO2009016639A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841785A2 (en) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2976814C (en) 2007-08-27 2022-12-13 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods for treating influenza
EP2280991B1 (en) 2008-04-18 2016-06-22 VaxInnate Corporation Deletion mutants of flagellin and methods of use
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
ES2727030T3 (es) 2010-08-23 2019-10-11 Kang Stem Biotech Co Ltd Composición farmacéutica para prevenir o tratar enfermedades inmunitarias o enfermedades inflamatorias, que contiene células madre tratadas con agonista de NOD2 o un producto cultivado del mismo
WO2012115715A2 (en) * 2011-02-21 2012-08-30 Vaxinnate Corporation Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use
CN103517713A (zh) * 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すh1n1インフルエンザの抗原
ES2490915B1 (es) * 2011-09-12 2015-09-17 Laboratorios Del Dr. Esteve, S.A. Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos
CA3207612A1 (en) * 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
HK1203983A1 (en) * 2012-04-02 2015-11-06 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
CN103055311B (zh) * 2012-12-28 2014-05-21 中山大学 一种传染性喉气管炎粘膜疫苗及其制备方法和应用
CA2897752A1 (en) * 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
JP6550072B2 (ja) * 2014-04-03 2019-07-24 バイオンドバックス ファーマシューティカルズ リミテッド 多量体マルチエピトープインフルエンザポリペプチドの組成物及びそれらの生成
SG10202108573TA (en) * 2016-02-03 2021-09-29 Cg Discovery Inc Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
JP2019064924A (ja) * 2016-02-24 2019-04-25 Agc株式会社 インフルエンザワクチン
WO2018126060A1 (en) 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
EP3730620A4 (en) * 2017-12-21 2022-01-05 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
JP7320601B2 (ja) * 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
US20220273790A1 (en) * 2019-06-18 2022-09-01 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
JP2023513720A (ja) * 2020-02-14 2023-04-03 ユニバーシティ オブ ワシントン 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用
US11149286B1 (en) * 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
US20230364261A1 (en) * 2020-09-21 2023-11-16 Sri International Targeted antigen delivery system and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4643992A (en) * 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4539205A (en) * 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) * 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) * 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9201139D0 (en) 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
DE69327599T2 (de) * 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
WO1994006421A1 (en) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine
US5683695A (en) * 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US7063967B2 (en) * 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
IL132886A0 (en) * 1997-05-20 2001-03-19 Galenica Pharmaceuticals Inc A triterpene saponin-lipophile conjugate a pharmaceutical composition containing the same and a vaccine containing the same
JP5132851B2 (ja) 1997-08-05 2013-01-30 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用
AU1145699A (en) * 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ATE215385T1 (de) * 1997-12-16 2002-04-15 Chiron Corp Verwendung von mikropartikeln mit submikron öl/wasser emulsionen
GB9807805D0 (en) 1998-04-09 1998-06-10 Smithkline Beecham Biolog Vaccine
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
EP1075276B1 (en) 1998-05-07 2007-10-17 Corixa Corporation Adjuvant composition and methods for its use
US6828416B1 (en) * 1998-08-21 2004-12-07 The United States Of America As Represented By The Department Of Health And Human Services Recombinant multivalent malarial vaccine against Plasmodium falciparum
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
EP1200109A4 (en) 1999-07-19 2005-06-15 Epimmune Inc USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
AU1075001A (en) 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
AU2001268662A1 (en) 2000-06-23 2002-01-08 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
WO2004080403A2 (en) 2003-03-07 2004-09-23 Merck & Co. Inc. Influenza virus vaccine
US7108679B2 (en) * 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
US7794731B2 (en) * 2004-12-16 2010-09-14 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of Yersinia pestis
JP2008524261A (ja) 2004-12-21 2008-07-10 バクシネート コーポレーション インフルエンザウイルスタンパク質の組成物およびその使用方法
EP1841785A2 (en) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2610667A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
US7260958B2 (en) * 2005-09-14 2007-08-28 National Taipei University Technology Electrohydrodynamic condenser device
CA2628379A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adminstration routes for priming/boosting with influenza vaccines
DK1968632T3 (da) * 2005-12-06 2012-07-16 Yeda Res & Dev Forbedret influenzavaccine
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2008039267A2 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
JP2010536878A (ja) 2007-08-21 2010-12-02 ダイナバックス テクノロジーズ コーポレイション インフルエンザタンパク質を製造および使用する組成物および方法

Similar Documents

Publication Publication Date Title
JP2010535026A5 (enExample)
US20240075125A1 (en) Expression systems
JP6957580B2 (ja) 新規多価ナノ粒子に基づくワクチン
HRP20150479T1 (hr) Multimeriäśna multiepitopska cjepiva protiv influence
Kim et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection
KR101736897B1 (ko) 인플루엔자 항원 수송 벡터 및 구조물
JP2014507146A5 (enExample)
JP2012501959A5 (enExample)
JP2012511914A5 (enExample)
JP2015506705A5 (enExample)
US11160858B2 (en) Live recombinant measles-M2 virus—its use in eliciting immunity against influenza viruses
WO2019092002A1 (en) Pharmaceutical compositions for treatment or prevention of viral infections
Du et al. Flu universal vaccines: new tricks on an old virus
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
Park et al. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge
Hong et al. Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development
JP2014527526A5 (enExample)
JP7403733B2 (ja) インフルエンザhaスプリットワクチンの製造方法
JP2016505538A5 (enExample)
CN103732249A (zh) 含有经修饰腺病毒载体的流感疫苗
Wang et al. Improving cross-protection against influenza virus using recombinant vaccinia vaccine expressing NP and M2 ectodomain tandem repeats
CN107344969A (zh) 一种纳米流感疫苗及构建方法和应用
RU2013102929A (ru) Пан-лиссавирусные вакцины против бешенства
JP2019534242A5 (enExample)
JP2014530610A5 (enExample)